DOCSLIB.ORG

United States

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
United States UNITED STATES BIOPHARMACEUTICALS 2020 BIOPHARMACEUTICALS UNITED STATES UNITED STATES BIOPHARMACEUTICALS 2020 Research and Development - Contract Services - Drug Discovery Academic Research Regulations and Compliance - East Coast Hubs - Logistics and Distribution Amos i m 0 0 5 Fredericton Timmins Quebec i m 0 0 4 The East Coast Corridor: MAINE i m Bangor The Heart of 0 0 American Biopharma 3 Montreal Augusta Dear Reader, i Ottawa m 0 VERMONT CANADA 0 2 Montpelier NEW HAMPSHIRE Portland Kingston i The United States Biopharmaceutical industry is widely envied m 0 0 Concord around the world, and for good reason. From gene editing, to cell- 1 Welcomebased to therapies, the 2020 toedition profoundly of the new US Biopharmaceuticalways of manipulating Industry immune Report, a jointcells GBR-CPhI to target analysis. cancers, Thetoday’s United science States is being Biopharmaceutical translated into industryprac- is Toronto widelytical envied treatments around forthe patients world, and at breakneck for good reason.speed. FromBiopharma gene editing,com- to MICHIGAN Albany BOSTON cell-basedpanies therapies, have achieved to profoundly remarkable new progressways of manipulating in advancing immune early dis cells- to Rochester MASSACHUSETTS targetease cancers, detection today’s and science enabling is being targeted translated treatments into practical with limited treatments side for NEW YORK patientseffects. at breakneck These innovations speed. Biopharma have catalyzed companies significant have reductionsachieved remark in - Buffalo Providence able theprogress number in advancingof deaths dueearly to disease cancer, detectionHIV/AIDS, andand enablingautoimmune targeted Hartford RHODE ISLAND treatmentsdiseases with across limited the side world. effects. This Theseprovides innovations reasons forhave optimism catalyzed that signifi - Lansing i 0m cant reductions in the number of deaths due to cancer, HIV/AIDS, and auto- Detroit 10 CONNECTICUT America’s dynamic life sciences industry will be able to collectively i immunerise diseasesto the occasion across the and world. defeat This the provides novel COVID-19 reasons forvirus optimism that is that m 0 America’s dynamic life sciences industry will be able to collectively rise to the Erie 0 2 bedeviling society today. NEW YORK occasion and defeat the novel COVID-19 virus that is bedeviling society today. Jersey City As we move through these uncertain times, it is crucial for inves- Cleveland PENNSYLVANIA As wetors, move pharmaceutical through these executives, uncertain times,and scientific it is crucial researchers for investors, involved pharma - TRENTON ceutical executives, and scientific researchers involved in the US biopharma- GREATER in the US biopharmaceutical industry to remain together and in- ceutical industry to remain together and informed. The way in which groups Pittsburgh Harrisburg PHILADELPHIA formed. The way in which groups across industry, academia, gov- across industry, academia, government, and the broader health-care system OHIO NEW JERSEY ernment, and the broader health-care system have come together Wilmington have tocome fight together this pandemic to fight thishave pandemicbeen inspiring. have beenIndeed, inspiring. continuing Indeed, to con- tinuingpartner to partner in this in way this willway be will critical be critical in successfully in successfully navigating navigating public public i Baltimore m health challenges of the future. That is the essence of why events like CPhI Columbus 0 health challenges of the future. That is the essence of why events 0 Dover 3 MARYLAND Northlike America CPhI Northexist. America exist. Annapolis Dayton Washington D.C. DELAWARE The followingThe following pages pages offer widespreadoffer widespread coverage coverage of the stateof the of state the USof thebiophar - maceuticalUS biopharmaceutical industry, including industry, big pharma including and its big blockbuster pharma and drugs, its block emerging- Cincinnati WEST biotech and their innovative drug pipelines, and the different service providers VIRGINIA buster drugs, emerging biotech and their innovative drug pipelines, acrossand the the value different chain, service from CDMO’s providers and across CRO’s the to value AI and chain, big fromdata CDplatform- companies. Charleston MO’s and CRO’s to AI and big data platform companies. VIRGINIA We sincerely hope that you have a great conference, full of business and net- Frankfort We sincerely hope that you have a great conference, full of business i Richmond workingand opportunities. networking opportunities. Thank you for Thank your participationyou for your inparticipation CPhI North in Amer - m 0 0 ica, and we hope you enjoy reading our 2020 edition of the United States Lexington 4 Norfolk CPhI North America, and we hope you enjoy reading our 2020 edi- Roanoke Biopharmaceuticaltion of the United Industry States Report. Biopharmaceutical Industry Report. N.C. Atlantic Ocean KENTUCKY DURHAM RESEARCH TRIANGLE CHAPEL HILL RALEIGH Asheville NORTH Knoxville i m 0 Charlotte CAROLINA 0 TENNESSEE 5 Chattanooga Greenville SOUTH Alice Pascoletti Anthony Pombal Columbia Managing DirectorDirector Brand Director Huntsville CAROLINA Global Business Reports CPhI North America Atlanta GEORGIA Augusta Charleston Savannah Montgomery Editorial Introducing the US 35. Interview with Ernst & Young 57. Interview with Eloxx Pharmaceuticals 75. Interview with Alira Health Industry Outlook Biopharmaceutical Industry 36. Interview with Signet Healthcare Partners 58. Responding to COVID-19 76. Interviews with CordenPharma Group Analysis 37. To List or not to List 59. Interview with Aphios and with Visikol 98. Conclusion 8. The Moral Imperative to Innovate 39. Interview with Burrage Capital 60. Commercializing Neuroscience 77. Interviews with Avēma Pharma Solutions 99. Comments from Nicos Group, 11. Interview with Porzio Life Sciences 61. Interview with Terran Biosciences and with ACG Capsules Pharmalex and Hart & Reed-Lane GBR provides unique 14. Interview with Nivagen Pharmaceuticals 62. Originating Discovery 78. Generics 100. Concluding Thoughts and first-hand analysis 15. Interview with Pfizer 63. Interview with Princeton 81. Interview with Advantice Health 102. Company Directory into all aspects of the US 16. Introducing the hubs Accelerating Pipelines: Entrepreneurship Council 82. Interview with Dr. Reddy’s Laboratories 104. Credits biopharmaceutical industry 20. Interview with BIONJ Drug Discovery and Development 64. Interview with Rutgers 83. Interview with Servier Group after months on the ground 22. Interview with MassBio 65. Interview with Roux Institute of 42. Top 10 U.S. Biopharmaceutical Northeastern University Companies Based on Revenue 8, 26, 43, 68, 43. Drug Development and Discovery Technology and USA BIOPHARMACEUTICALS 2020 44. Interview with Onosec Medical Industry Explorations The Biopharma Investment Climate Regulatory Services Global Business Reports 86, 98.... 47. Interview with Goldfinch Bio Contract Manufacturing 26. From Bull Market to Uncertainty This research has been conducted by 48. Advancing Oncology and Generics 86. Disruptive Technology Lucrezia Falcidia, Jason Spizer and 28. Interview with Third Rock Ventures 49. Interview with Stemsynergy Therapeutics 87. Interview with AiCure Maria Filippova Barnachisnkaya 29. Interview with XOMA 51. Interview with Cyclacel Pharmaceuticals 68. Contract Development and Manufacturing 89. Interview with Decision Resources Group Edited by Mungo Smith 30. Interview with Atlas Venture 52. Interview with Hillstream Biopharma 70. Interview with Cambrex 90. Interview with Pharmafusion Graphic design by Gonzalo Da Cunha 31. Interview with J.W. Childs Associates 53. Interview with InteRNA Technologies 71. Interview with GVK BIO 91. Interview with Cardinal Health A Global Business Reports Publication 32. Merger Spree 54. Expanding Therapeutic Focus 72. Interview with Piramal Global Pharma 92. Regulatory Services For updated industry news from our 34. Interview with J.P. Morgan on-the-ground teams around the world, 55. Interview with AzurRX Biopharma 73. Interview with Sunrise Pharmaceuticals 93. Interview with Systech International please visit our website at gbreports.com, subscribe to our Commercial Banking 56. Interview with Hepion Pharmaceuticals 74. Interview with Contract Pharmacal Corp 94. Interviews with Adents and with Tracelink newsletter by signing up to our VIP list through our website, or follow us on Twitter: @GBReports CONTENTS / USA Biopharmaceuticals 2020 Exclusive Interviews Olympia Washington CANADA Leading industry figures North Maine Salem Dakota Minnesota share their insights and Helena Montana Bismarck exciting new developments Augusta Idaho Montpelier with GBR Oregon New Vermont United States Boise Hampshire St. Paul New York Concord of America South Pierre Albany Boston 11, 15, 55, 56, Dakota Wisconsin Michigan International Boundary State Boundary Wyoming Providence Lansing Hartford Rhode Island 81, 87... State Capital Madison Connecticut Pennsylvania Iowa Carson City Cheyenne Harrisburg Trenton N Nebraska Salt Lake City Des Moines Sacramento Illinois Columbus Ohio Dover Nevada Lincoln Indianapolis Delaware Denver Springfield Annapolis Maryland Utah Topeka Indiana Washington D.C. Virginia Colorado Charleston West Richmond Kansas Virginia Atlantic Ocean California Jefferson Frankfort City Missouri Kentucky Raleigh Industry Arizona Santa Fe North Carolina Oklahoma Nashville Tennessee Little Thoughts Oklahoma Phoenix Rock Columbia City New Mexico Atlanta
Load more

Recommended publications
  • Q1 09 Fundraising Update
    www.preqin.com Preqin Ltd. Q1 2009 Private Equity Fundraising Update Special Report 23rd April 2009 © 2009 Preqin Ltd. / www.preqin.com 2 ◄ Q1 2009 Fundraising Update Q1 Overview The Coming Turn in Fundraising As everyone is painfully aware, Fig. 1: fundraising conditions in Q1 2009 were dire. Looking across all private Final Close vs. Original Target equity fund types (venture, buyout, mezzanine, distressed, fund of funds etc.), a total of only 78 funds worldwide achieved fi nal closes, raising $49 billion between them. This represents a return to the kind of levels we were experiencing in 2004 following the trough of the previous fundraising depression. As bad as these headline statistics are, they actually disguise just how bad fundraising conditions had become. Faced with a very diffi cult market, many managers who were on the road decided to cut their losses and declare fi nal closes for funds that may have two-thirds of all funds closed were equity fundraising is set to rebound actually raised most of their funding achieving between 80% and 120% strongly: in interim closes six or twelve months of their targeted amount. Around previously – hence much of the money 15% of funds fell short by more than • LP Intentions: Preqin regularly in the ‘fi nal closes’ total was actually 20%, while 20-25% of funds exceeded surveys LP intentions, and even raised in previous quarters. Very little their targets by 20% or more. The in the depths of the credit crisis new money was committed in Q1 situation deteriorated markedly in Q4 in December 2008 these LPs 2009.
    [Show full text]
  • The Art of Exiteering
    THE ART OF EXITEERING In conversation with European tech founders NOTION INSIGHTS Start. Grow. Succeed 1 Notion Insights is published by Notion Capital, 91 Wimpole Street, London W1G 0EF. Registered address: Third Floor, 1 New Fetter Lane, London EC4A 1AN Contact Notion Capital is a trading name of The Fund Incubator +44 (0)845 498 9393 Limited – registered in Scotland Co No SC218683. [email protected] MBM COMMERCIAL, 5th Floor 125 Princes Street, Edinburgh, Scotland, EH2 4AD. Content Authorised and Regulated by the Financial For opportunities to contribute to future editions Conduct Authority. of Notion Insights please contact Kate Hyslop. Reproduction in whole or in part without written Design permission is strictly prohibited. [email protected] © 2017 Notion Capital. All rights reserved. The Art of Exiteering is brought to you by Supported by 2 3 Contents The Art of Exiteering: In conversation with European tech founders 6 / Introduction 44 / Professional Perspectives 82 / The Qlik Story Stephen Chandler Daniel Glazer, Steven Bernard Måns Hultman and Bradley Finkelstein 8 / The Advisor’s View – from the EY Fast Growth Team Wilson Sonsini Goodrich & Rosati 86 / Professional Perspectives Kevin McGovern, Advisor 10/ Executive Summary 49 / The Hybris Story The Art of Exiteering: In conversation Stefan Schmidt 91 / The Thunderhead Story with European tech founders Glen Manchester 54 / The MessgeLabs Story 16 / The Astonishing Tribe Story Ben White, Jos White, Stephen Chandler 96 / The Scansafe Story Hampus Jakobsson and Chris
    [Show full text]
  • Pharma Asset Insights POWERED by SCRIP and in VIVO
    Pharma intelligence Pharma Asset Insights POWERED BY SCRIP AND IN VIVO Bringing science innovation and partnering news to the biopharmaceutical business community Pharma intelligence Innovation in the pharmaceutical industry has never been more exciting, and complicated. Disruptive technologies, such as artificial intelligence and digital health tools, and advanced therapeutic modalities including cell and gene therapies and antisense oligonucleotides demand that all health care stakeholders make efforts to move into the next generation of patient care and centricity. Funding for start-ups has reached an inflection point, with venture capital money flowing into companies at a rapid speed and at record-high amounts, particularly for those located in Europe. In 2013 only three life science venture capital rounds surpassed $100 million; by the first quarter of 2018, those financings have become more of the rule than the exception, as 10 venture rounds worth over $100 million were completed, led by a massive $500 million late-stage funding from Moderna Therapeutics. Many of these firms have progressed to the IPO stage, where markets have been very favorable over the past couple years. Indeed, 11 biopharma IPOs netted an aggregate $1 billion in Q1 2018, and included a $56 million offering from BioXcel Therapeutics, which is using artificial intelligence to identify the most promising neurological and immune-oncology drug candidates to advance. Overall, companies involved in mining and applying predictive analytics to big datasets have been well funded recently, including BenevolentAI, which closed on a $115 million financing, and Pear Therapeutics, a digital health company that has raised $50 million and signed on Novartis to market its reSET digital therapeutics product for substance abuse.
    [Show full text]
  • 3Rd FCF Life Science Venture Capital Report
    FCF Life Science Research 3rd Life Science Venture Capital Report – Financing Trends in Europe and the US Fungi Penicillium Part of FCF Life Science Research Series Executive Summary FCF Overview Funding Development in 2018 Life Sciences: A closer Look C r o s s - border Investment Activity Investor Analysis Life Science Exits 2 Executive Summary The FCF Life Science Venture Capital FCF Life Science Venture Capital Report Recipients Report is a is a comprehensive, standardized analysis for biotechnology, The FCF Life Science Venture Capital Report targets the following standardized report pharmaceutical and medical technology companies, examining recipients: focusing on venture recent venture capital deal trends in the European life science ▪ Corporates / Executives ▪ Venture capital investors capital deal industry ▪ Institutional investors ▪ Family Offices / High- characteristics in the ▪ Private equity investors net-worth individuals biotechnology, ▪ Advisors Selection of Companies pharmaceutical and medical technology The selection of companies is based on the following criteria: Availability segments, and can be used as a quick ▪ Companies operating in the biotechnology, pharmaceutical, The FCF Life Science Venture Capital Report is available on FCF’s reference for medical technology, services or other life science related sectors website at “https://www.fcf.de/de/research/life-science-research“ investors, corporates ▪ Sole focus on transactions involving European life science and professionals companies Data ▪ The therapeutics sector is further divided into the following All input data is provided by Pitchbook, S&P Capital IQ or More advanced, indications: Oncology, Central Nervous System, Infectious GlobalData and is not independently verified by FCF. Ratio and detailed and / or Diseases, Immunology, Ophthalmology, Rare Diseases, multiple calculations are driven based on the input data available.
    [Show full text]
  • Life Sciences Venture Equity Market Review: the Evolving Role of Crossover Investors
    Life Sciences Venture Equity Market Review: The Evolving Role of Crossover Investors June 2021 Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC. In Europe such services are offered through Torreya Partners (Europe) LLP, which is authorized and regulated by the UK Financial Conduct Authority. The Market for Equity Privates in Life Sciences TORREYA | PRIVATE LIFE SCIENCES VENTURE FINANCING MARKET REVIEW – JUNE 2021 2 Total Private Venture Financing Volume: 2000-2021 H1 Given volumes in the first half of this year, there is little doubt that 2021 will shape up to be the most active year in history for private financing activity in the life sciences sector. Total Volume of Private Biopharma, Diagnostics and Tools 50000 Financing Rounds by Year Jan 2000 - June 2021 600 (deals over $25mm, excluding medical devices, worldwide) 45000 523 500 40000 35000 373 400 356 30000 334 25000 300 20000 224 226 Transaction Transaction Count 184 200 15000 145 138 121 122 111 10000 109 88 97 96 81 72 100 Aggregate Aggregate Dollar Volume of Private Financings ($mm) 55 5000 40 35 23 0 0 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 H1 Transaction Count Dollar Volume ($mm) Source: Torreya analysis and records, CapitalIQ and Crunchbase TORREYA | PRIVATE LIFE SCIENCES VENTURE FINANCING MARKET REVIEW – JUNE 2021 3 Fresh Venture Capital Flowing into Life Science Sector We are on track to see record amount raised in life science venture capital in 2021.
    [Show full text]
  • The View Beyond Venture Capital
    BUILDING A BUSINESS The view beyond venture capital Dennis Ford & Barbara Nelsen Fundraising is an integral part of almost every young biotech’s business strategy, yet many entrepreneurs do not have a systematic approach for identifying and prioritizing potential investors—many of whom work outside of traditional venture capital. re you a researcher looking to start a Why and how did the funding landscape During the downturns, it quickly became Anew venture around a discovery made change? apparent that entrusting capital to third-party in your laboratory? Perhaps you have already The big changes in the life science investor alternative fund managers was no longer an raised some seed money from your friends landscape start with the venture capitalist effective strategy, and investors began to with- and family and are now seeking funds to sus- (VC). In the past, venture capital funds were draw capital. The main reason for the with- tain and expand your startup. In the past, the typically capitalized by large institutional drawal (especially from VCs in the early-stage next step on your road to commercialization investors that consisted of pensions, endow- life science space) was generally meager returns would doubtless have been to seek funding ments, foundations and large family offices across the asset class; despite the high risk and from angels and venture capital funds; today, with $100 million to $1 billion in capital long lockup periods that investors accepted in however, the environment for financing an under management. Traditionally, the major- return for a promise of premium performance, early-stage life science venture looks strik- ity of these institutions maintained a low-risk, VCs were often not returning any more capital ingly different from that familiar landscape low-return portfolio of stocks and bonds that than investors would have earned by making of past decades.
    [Show full text]
  • UNITED STATES SECURITIES and EXCHANGE COMMISSION Washington, D.C
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* AVROBIO, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 05455M100 (CUSIP Number) Atlas Venture Attention: Ommer Chohan, Chief Financial Officer 400 Technology Square, 10th Floor Cambridge, MA 02139 USA (857) 201-2700 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) July 19, 2019 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☒ Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
    [Show full text]
  • Biotechnology Startups Research Report
    GLOBAL BUSINESS CONFIDENCE REPORT 4th Qtr. 2019 B IOTECH NOLOGY STARTUPS RESEARCH REPORT 4th Quarter 2019 www.tradecouncil.org www.qibcertification.org International Trade Council www.tradecouncil.org www.goglobalawards.org Page 1 MARKET OVERVIEW REPORT FOR ENTERPRISE ESTONIA Table of Contents Overview ........................................................................................................................................................................... 3 Industry Definition .......................................................................................................................................................................................... 3 Sectoral Definitions ........................................................................................................................................................................................ 3 Main Activities .................................................................................................................................................................................................. 4 Associated Industries ..................................................................................................................................................................................... 4 Industry at a Glance ......................................................................................................................................................... 5 Industry Overview ..........................................................................................................................................................................................
    [Show full text]
  • REPORT 2015 Vol. 6
    REPORT 2015 vol. 6 Forward-thinking articles from our global network of innovation ecosystem experts KFR Staff KF Board of Directors Publisher Brian Dovey, Chairman Kauffman Fellows Press Domain Associates Executive Editor Tom Baruch Phil Wickham Formation 8 Managing Editor Jason Green Anna F.Doherty Emergence Capital Partners Associate Editor Karen Kerr Leslie F. Peters Agile Equities, LLC Production and Design Audrey MacLean Anna F. Doherty Stanford University Leslie F. Peters Susan Mason Printer Aligned Partners Almaden Press www.almadenpress.com Jenny Rooke Copyright Fidelity Biosciences © 2015 Kauffman Fellows. All rights reserved. Christian Weddell Under no circumstances shall any of the information provided herein be construed as investment advice of any kind. Copan About the Editor Phil Wickham Anna F. Doherty is an accomplished editor and writing Kauffman Fellows coach with a unique collaborative focus in her work. She has 20 years of editing experience on three continents in a variety of business industries. Through her firm, Together Editing & Design, she has offered a full suite of writing, design, and publishing services to Kauffman Fellows since 2009. Leslie F. Peters is the Lead Designer on the TE&D team. www.togetherediting.com www.kauffmanfellows.org Town & Country Village • 855 El Camino Real, Suite 12 • Palo Alto, CA 94301 Phone: 650-561-7450 • Fax: 650-561-7451 Venturing into the Industry: Lessons Learned from a VCpreneur Ahmad Takatkah Class 17 My life has been swinging between in Empretec,2 an international entrepreneurship and venture capital for more entrepreneurship training program than ten years now. In each cycle, I get closer that is managed by the United Nations and to my goal, even as I refine my goals further.
    [Show full text]
  • Insurance Technology Four Trillion Dollar Industry Finally Goes Digital
    Insurance Technology Four Trillion Dollar Industry Finally Goes Digital Greg Roth, Partner Ben Howe, CEO Matei Sanders, Principal Catch the Wave . Insurance Technology is riding a wave of innovation and investment that is attempting to do in a few short years what the insurance industry itself has failed to do over the last decade: a complete digital migration across all business processes . With $4.6 Trillion in global annual premiums, or 5.6% of global GDP, the insurance industry is a highly attractive market where incumbents have been slow to embrace innovation . There are three competitive threats at work in the insurance market and they all point to Technology Disruption: (1) an explosion of well funded, InsureTech startups; (2) the feared entry of the B2C tech “titans” (i.e. Google, Amazon, Facebook, etc.); and (3) incumbents racing to adopt modern enabling technologies . Investors can sense the opportunity: InsureTech investments are up six-fold over the last five years across at all stages of funding . Whereas this first wave has primarily focused on distribution, a second wave is taking aim at how insurance products are designed, priced, and operated . Incumbents’ initial reaction has been to partner and invest mostly in enabling technology . These market forces point to increased M&A activity as customer demand will make InsureTech solutions key to an insurer’s customer acquisition and retention strategy (# of Private Insurance Tech Investments Ramping Placements) 200 173 150 122 100 91 63 46 50 28 0 2011 2012 2013 2014 2015 2016 Source: Capital IQ, CB Insights 2 Investment in Technology Pays Dividends Investment in Technology Translates to .
    [Show full text]
  • European Life Sciences Start-Ups Maintain Early Investor Allure
    invivo.pharmaintelligence.informa.com FEBRUARY 2018 Invol. 36 ❚ no. 02 Vivopharma intelligence ❚ informa European Life Sciences Start-Ups Maintain Early Investor Allure BY JOHN HODGSON AND MIKE WARD US Medtechs Lag In Global Shift IO Is Making Pharma Step Up GE Healthcare: To Value-Based Care Its Diagnostics Game The Strategic Language Of Software invivo.pharmaintelligence.informa.com ❚ LIFE SCIENCES INVESTING LIFE SCIENCES INVESTING ❚ European Life Sciences Start-Ups Maintain Venture capital investment in life sciences companies continues to rise. In 2017, biopharma and medtech start-ups raised $19.7 billion worldwide. European businesses Early Investor Allure retained a robust share of that global take and investors expect that trend to continue. BY JOHN HODGSON AND MIKE WARD t has never been a better have put similar amounts of money into time for life sciences start- finance ventures or Internet companies ups to raise money from or into consumer enterprise or business venture sources. In 2017, services. Looking across all venture in- according to data compiled vestments, health-related VC is around by Informa Pharma Intel- As if to prove that 20% of the $22 billion total in Europe, ligence, venture capitalists estimated by FinSMEs, a pan-sectoral invested a total of $19.7 bil- author Douglas investment website. Biotech accounts for lion in the sector across the around 14% of the total and medtech for globe – some $15.1 billion Adams was right all about another 3%. Shutterstock: Copyright Info Copyright Shutterstock: allocated to 512 biopharma-focused op- Life sciences companies come out well portunities while $4.6 billion was invested along, the leading B as recipients of big ticket venture back- Iin 107 medtech businesses.
    [Show full text]
  • The Healthcare Technology Venture Market in Europe, UK and Yorkshire & Humber About Library Innovation Group (L.I
    L.I. Group The Healthcare Technology Venture Market in Europe, UK and Yorkshire & Humber About Library Innovation Group (L.I. Group) The L.I. Group was formed as a spin-out company from the Library House Consulting Department. The company uses established evidence-based research methodologies to deliver strategic insights into innovation-led companies and markets. It also advises public and private sector organisations on strategic issues that involve technology, innovation, entrepreneurship and finance. Project Team: Martin Holi Alexander Jan Stephen Mounsey Dr Jonathan Lawton Dr Siobhán Ní Chonaill Malgosia Rozycka For more information about the contents of this report, please contact: i L.I. Group St John’s Innovation Centre Cowley Road Cambridge CB4 OWS United Kingdom www.li-group.co.uk [email protected] Access To Finance For Healthcare Technologies Programme Access to Finance for Healthcare Technologies is an investment readiness programme established by Yorkshire Forward to assist companies in the Health Technology sectors. The programme addresses three key factors relevant to the Yorkshire & Humber region: • the opportunity to develop investment markets, especially for companies in complex and challenging markets such as healthcare; • the opportunity to engage talented business support professionals able to provide advice and guidance on raising finance in general and especially in this sector; and • a shortage of existing successfully venture backed companies to act as role models, explain the process and showcase the benefits. The programme is scheduled to run for an initial period of three years from January 2009 and is delivered by a consortium of three companies, led by Grant Thornton UK LLP and including Quotec and BITECIC.
    [Show full text]